−0.090AUD
−8.00 MAUD
83.62 MAUD
171.66 M
About SOMNOMED LIMITED
Sector
Industry
Headquarters
Sydney
Website
Founded
1987
ISIN
AU000000SOM1
FIGI
BBG000Q6QG76
SomnoMed Ltd. engages in the production and sale of devices for the oral treatment of sleep related disorders. Its products include SomnoDent, SomMorning Repositioner, SomnoBrux, SomTabs, and Sunrise Sleep Test. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded in 2004 and is headquartered in Sydney, Australia.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SOM is 0.20 AUD — it has decreased by 2.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange SOMNOMED LIMITED stocks are traded under the ticker SOM.
SOMNOMED LIMITED is going to release the next earnings report on Aug 29, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for SOMNOMED LIMITED has a max estimate of 0.35 AUD and a min estimate of 0.35 AUD.
SOM earnings for the last quarter are −0.03 AUD whereas the estimation was −0.01 AUD which accounts for −124.82% surprise. Estimated earnings for the next quarter are −0.02 AUD. See more details about SOMNOMED LIMITED earnings.
SOMNOMED LIMITED revenue for the last quarter amounts to 43.70 M AUD despite the estimated figure of 44.50 M AUD. In the next quarter revenue is expected to reach 44.00 M AUD.
Yes, you can track SOMNOMED LIMITED financials in yearly and quarterly reports right on TradingView.
Like other stocks, SOM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOMNOMED LIMITED stock right from TradingView charts — choose your broker and connect to your account.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SOMNOMED LIMITED EBITDA is −857.28 K AUD, and current EBITDA margin is 1.25%. See more stats in SOMNOMED LIMITED financial statements.